ZURICH (Reuters) - Swiss drugmaker Novartis confirmed 2018 growth targets on Thursday as new Chief Executive Officer Vas Narasimhan said he was encouraged by first-quarter performance by his cancer drugs portfolio and a resurgent Alcon eye care unit.